Biomea Fusion Inc

NASDAQ BMEA

Data sourced from

and

Download Data

Biomea Fusion Inc Cash Taxes 5 year CAGR for the Trailing 12 Months (TTM) ending September 30, 2023

Biomea Fusion Inc Cash Taxes 5 year CAGR is NA for the Trailing 12 Months (TTM) ending September 30, 2023. Cash taxes represent the total amount of cash paid for income taxes, including both current and deferred taxes. It is calculated by summing the income tax provision and any non-cash tax-related items. This metric provides insight into the company's cash outflows related to taxes, which can impact its overall cash position and liquidity. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Biomea Fusion Inc Cash Taxes for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -1.91 M, a -1,086.60% change year over year.
Biomea Fusion Inc Cash Taxes for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 194.00 K.

NASDAQ: BMEA

Biomea Fusion Inc

CEO	Mr. Thomas Andrew Butler
IPO Date	April 16, 2021
Location	United States
Headquarters	900 Middlefield Road, Redwood City, CA, United States, 94063
Employees	110
Sector	Healthcare
Industry	Biotechnology

Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Key trends